Novozymes A/S
NSIS-B.CO
Get informed when a big investor buys or sells
+ FollowMarket Cap$202.86B
Close$
$-5.03
101.1% downside
Current Fair Value
101.1% downsideOvervalued by 101.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $202.86 Billion |
|---|---|
| Enterprise Value | - |
| Dividend Yield | $6.60 (1.52%) |
| Earnings per Share | $1.25 |
| Beta | 0.62 |
| Outstanding Shares | 466,246,618 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | 41.58 |
|---|---|
| PEG | 4.97 |
| Price to Sales | 49.89 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 20, 2026
EPS Estimate
$3.95
Average shareholder expectationRevenue Estimate
$8.28 B
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$5.15
Average shareholder expectationRevenue Estimate
$8.29 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Novozymes A/S
11,098 employees
CEO: Ester Baiget Established in 1925 and based in Bagsvaerd, Denmark, Novozymes A/S is a global provider of biological solutions, specializing in the development and sale of industrial enzymes, microorganisms, and probiotics. The company's reach extends ...